Fatty Acid Methyl Esters and Solutol HS 15 Confer Neuroprotection after Focal and Global Cerebral Ischemia

Hung Wen Lin, Isabel Saul, Victoria L. Gresia, Jake T. Neumann, Kunjan R Dave, Miguel Perez-Pinzon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We previously showed that palmitic acid methyl ester (PAME) and stearic acid methyl ester (SAME) are simultaneously released from the sympathetic ganglion and PAME possesses potent vasodilatory properties which may be important in cerebral ischemia. Since PAME is a potent vasodilator simultaneously released with SAME, our hypothesis was that PAME/SAME confers neuroprotection in rat models of focal/global cerebral ischemia. We also examined the neuroprotective properties of Solutol HS15, a clinically approved excipient because it possesses similar fatty acid compositions as PAME/SAME. Asphyxial cardiac arrest (ACA, 6 min) was performed 30 min after PAME/SAME treatment (0.02 mg/kg, IV). Solutol HS15 (2 ml/kg, IP) was injected chronically for 14 days (once daily). Histopathology of hippocampal CA1 neurons was assessed 7 days after ACA. For focal ischemia experiments, PAME, SAME, or Solutol HS15 was administered following reperfusion after 2 h of middle cerebral artery occlusion (MCAO). 2,3,5-Triphenyltetrazolium staining of the brain was performed 24 h after MCAO and the infarct volume was quantified. Following ACA, the number of surviving hippocampal neurons was enhanced by PAME-treated (68 %), SAME-treated (69 %), and Solutol-treated HS15 (68 %) rats as compared to ACA only-treated groups. Infarct volume was decreased by PAME (83 %), SAME (68 %), and Solutol HS15 (78 %) as compared to saline (vehicle) in MCAO-treated animals. PAME, SAME, and Solutol HS15 provide robust neuroprotection in both paradigms of ischemia. This may prove therapeutically beneficial since Solutol HS15 is already administered as a solublizing agent to patients. With proper timing and dosage, administration of Solutol HS15 and PAME/SAME can be an effective therapy against cerebral ischemia.

Original languageEnglish
Pages (from-to)109-117
Number of pages9
JournalTranslational Stroke Research
Volume5
Issue number1
DOIs
StatePublished - Feb 1 2014

Fingerprint

Brain Ischemia
Esters
Fatty Acids
Middle Cerebral Artery Infarction
Solutol HS 15
methyl palmitate
Neuroprotection
Ischemia
stearic acid
Neurons
Sympathetic Ganglia
Excipients
Proxy
Heart Arrest
Vasodilator Agents
Reperfusion
Staining and Labeling

Keywords

  • Asphyxial cardiac arrest
  • Middle cerebral artery occlusion
  • Neuroprotection
  • Palmitic acid methyl ester
  • Stearic acid methyl ester

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Fatty Acid Methyl Esters and Solutol HS 15 Confer Neuroprotection after Focal and Global Cerebral Ischemia. / Wen Lin, Hung; Saul, Isabel; Gresia, Victoria L.; Neumann, Jake T.; Dave, Kunjan R; Perez-Pinzon, Miguel.

In: Translational Stroke Research, Vol. 5, No. 1, 01.02.2014, p. 109-117.

Research output: Contribution to journalArticle

@article{3516203e1195478fb5fc4fe3dfa0b805,
title = "Fatty Acid Methyl Esters and Solutol HS 15 Confer Neuroprotection after Focal and Global Cerebral Ischemia",
abstract = "We previously showed that palmitic acid methyl ester (PAME) and stearic acid methyl ester (SAME) are simultaneously released from the sympathetic ganglion and PAME possesses potent vasodilatory properties which may be important in cerebral ischemia. Since PAME is a potent vasodilator simultaneously released with SAME, our hypothesis was that PAME/SAME confers neuroprotection in rat models of focal/global cerebral ischemia. We also examined the neuroprotective properties of Solutol HS15, a clinically approved excipient because it possesses similar fatty acid compositions as PAME/SAME. Asphyxial cardiac arrest (ACA, 6 min) was performed 30 min after PAME/SAME treatment (0.02 mg/kg, IV). Solutol HS15 (2 ml/kg, IP) was injected chronically for 14 days (once daily). Histopathology of hippocampal CA1 neurons was assessed 7 days after ACA. For focal ischemia experiments, PAME, SAME, or Solutol HS15 was administered following reperfusion after 2 h of middle cerebral artery occlusion (MCAO). 2,3,5-Triphenyltetrazolium staining of the brain was performed 24 h after MCAO and the infarct volume was quantified. Following ACA, the number of surviving hippocampal neurons was enhanced by PAME-treated (68 {\%}), SAME-treated (69 {\%}), and Solutol-treated HS15 (68 {\%}) rats as compared to ACA only-treated groups. Infarct volume was decreased by PAME (83 {\%}), SAME (68 {\%}), and Solutol HS15 (78 {\%}) as compared to saline (vehicle) in MCAO-treated animals. PAME, SAME, and Solutol HS15 provide robust neuroprotection in both paradigms of ischemia. This may prove therapeutically beneficial since Solutol HS15 is already administered as a solublizing agent to patients. With proper timing and dosage, administration of Solutol HS15 and PAME/SAME can be an effective therapy against cerebral ischemia.",
keywords = "Asphyxial cardiac arrest, Middle cerebral artery occlusion, Neuroprotection, Palmitic acid methyl ester, Stearic acid methyl ester",
author = "{Wen Lin}, Hung and Isabel Saul and Gresia, {Victoria L.} and Neumann, {Jake T.} and Dave, {Kunjan R} and Miguel Perez-Pinzon",
year = "2014",
month = "2",
day = "1",
doi = "10.1007/s12975-013-0276-z",
language = "English",
volume = "5",
pages = "109--117",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "1",

}

TY - JOUR

T1 - Fatty Acid Methyl Esters and Solutol HS 15 Confer Neuroprotection after Focal and Global Cerebral Ischemia

AU - Wen Lin, Hung

AU - Saul, Isabel

AU - Gresia, Victoria L.

AU - Neumann, Jake T.

AU - Dave, Kunjan R

AU - Perez-Pinzon, Miguel

PY - 2014/2/1

Y1 - 2014/2/1

N2 - We previously showed that palmitic acid methyl ester (PAME) and stearic acid methyl ester (SAME) are simultaneously released from the sympathetic ganglion and PAME possesses potent vasodilatory properties which may be important in cerebral ischemia. Since PAME is a potent vasodilator simultaneously released with SAME, our hypothesis was that PAME/SAME confers neuroprotection in rat models of focal/global cerebral ischemia. We also examined the neuroprotective properties of Solutol HS15, a clinically approved excipient because it possesses similar fatty acid compositions as PAME/SAME. Asphyxial cardiac arrest (ACA, 6 min) was performed 30 min after PAME/SAME treatment (0.02 mg/kg, IV). Solutol HS15 (2 ml/kg, IP) was injected chronically for 14 days (once daily). Histopathology of hippocampal CA1 neurons was assessed 7 days after ACA. For focal ischemia experiments, PAME, SAME, or Solutol HS15 was administered following reperfusion after 2 h of middle cerebral artery occlusion (MCAO). 2,3,5-Triphenyltetrazolium staining of the brain was performed 24 h after MCAO and the infarct volume was quantified. Following ACA, the number of surviving hippocampal neurons was enhanced by PAME-treated (68 %), SAME-treated (69 %), and Solutol-treated HS15 (68 %) rats as compared to ACA only-treated groups. Infarct volume was decreased by PAME (83 %), SAME (68 %), and Solutol HS15 (78 %) as compared to saline (vehicle) in MCAO-treated animals. PAME, SAME, and Solutol HS15 provide robust neuroprotection in both paradigms of ischemia. This may prove therapeutically beneficial since Solutol HS15 is already administered as a solublizing agent to patients. With proper timing and dosage, administration of Solutol HS15 and PAME/SAME can be an effective therapy against cerebral ischemia.

AB - We previously showed that palmitic acid methyl ester (PAME) and stearic acid methyl ester (SAME) are simultaneously released from the sympathetic ganglion and PAME possesses potent vasodilatory properties which may be important in cerebral ischemia. Since PAME is a potent vasodilator simultaneously released with SAME, our hypothesis was that PAME/SAME confers neuroprotection in rat models of focal/global cerebral ischemia. We also examined the neuroprotective properties of Solutol HS15, a clinically approved excipient because it possesses similar fatty acid compositions as PAME/SAME. Asphyxial cardiac arrest (ACA, 6 min) was performed 30 min after PAME/SAME treatment (0.02 mg/kg, IV). Solutol HS15 (2 ml/kg, IP) was injected chronically for 14 days (once daily). Histopathology of hippocampal CA1 neurons was assessed 7 days after ACA. For focal ischemia experiments, PAME, SAME, or Solutol HS15 was administered following reperfusion after 2 h of middle cerebral artery occlusion (MCAO). 2,3,5-Triphenyltetrazolium staining of the brain was performed 24 h after MCAO and the infarct volume was quantified. Following ACA, the number of surviving hippocampal neurons was enhanced by PAME-treated (68 %), SAME-treated (69 %), and Solutol-treated HS15 (68 %) rats as compared to ACA only-treated groups. Infarct volume was decreased by PAME (83 %), SAME (68 %), and Solutol HS15 (78 %) as compared to saline (vehicle) in MCAO-treated animals. PAME, SAME, and Solutol HS15 provide robust neuroprotection in both paradigms of ischemia. This may prove therapeutically beneficial since Solutol HS15 is already administered as a solublizing agent to patients. With proper timing and dosage, administration of Solutol HS15 and PAME/SAME can be an effective therapy against cerebral ischemia.

KW - Asphyxial cardiac arrest

KW - Middle cerebral artery occlusion

KW - Neuroprotection

KW - Palmitic acid methyl ester

KW - Stearic acid methyl ester

UR - http://www.scopus.com/inward/record.url?scp=84893737836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893737836&partnerID=8YFLogxK

U2 - 10.1007/s12975-013-0276-z

DO - 10.1007/s12975-013-0276-z

M3 - Article

C2 - 24323706

AN - SCOPUS:84893737836

VL - 5

SP - 109

EP - 117

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 1

ER -